Inhibition of nucleophosmin 1 suppresses colorectal cancer tumor growth of patient -derived xenografts via activation of p53 and inhibition of AKT

References

• Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56:379–390. doi:10.1016/0092-8674(89)90241-9.
   PubMed Web of Science ®Google Scholar
• Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6:493–505. doi:10.1038/nrc1885.
   PubMed Web of Science ®Google Scholar
• Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, Fu J, Lai PBS. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer. 2007;96:477–484. doi:10.1038/sj.bjc.6603574.
   PubMed Web of Science ®Google Scholar
• Pianta A, Puppin C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, Deganuto M, Paron I, Tell G, Puxeddu E, et al. Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun. 2010;397:499–504. doi:10.1016/j.bbrc.2010.05.142.
   PubMed Web of Science ®Google Scholar
• Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosman FT. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol. 1996;178:48–52.
   PubMed Web of Science ®Google Scholar
• Tsui KH, Juang HH, Lee TH, Chang PL, Chen CL, Yung BY. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin. 2008;29:364–370. doi:10.1111/j.1745-7254.2008.00747.x.
   PubMed Web of Science ®Google Scholar
• Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate. 1999;39:298–304.
   PubMed Web of Science ®Google Scholar
• Wong JC, Hasan MR, Rahman M, Yu AC, Chan SK, Schaeffer DF, Kennecke HF, Lim HJ, Owen D, Tai IT, et al. Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence. Int J Cancer. 2013;133:1567–1577. doi:10.1002/ijc.28180.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang F, Zhang XF, Qi LS, Yang L, Guo H, Zhang N. Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells. J Biomed Sci. 2012;19:53. doi:10.1186/1423-0127-19-53.
   PubMed Web of Science ®Google Scholar
• Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007;60:1112–1116. doi:10.1136/jcp.2006.044537.
   PubMed Web of Science ®Google Scholar
• Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu J-H, Zhang L-J, Su X-D, Wu Q-L, et al. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol. 2009;27:1091–1099. doi:10.1200/JCO.2008.16.6991.
   PubMed Web of Science ®Google Scholar
• Wagner HE, Thomas P, Wolf BC, Zamcheck N, Jessup JM, Steele GD Jr. Characterization of the tumorigenic and metastatic potential of a poorly differentiated human colon cancer cell line. Invasion Metastasis. 1990;10:253–266.
   PubMedGoogle Scholar
• Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene. 2008;27:4210–4220. doi:10.1038/onc.2008.54.
   PubMed Web of Science ®Google Scholar
• Kern DH, Morgan CR, Hildebrand-Zanki SU. In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res. 1988;48:117–121.
   PubMed Web of Science ®Google Scholar
• Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol. 1998;41:385–390. doi:10.1007/s002800050755.
   PubMed Web of Science ®Google Scholar
• Rahman M, Selvarajan K, Hasan MR, Chan AP, Jin C, Kim J, Chan SK, Le ND, Kim Y-B, Tai IT, et al. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia. 2012;14:624–633. doi:10.1593/neo.12486.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446. doi:10.1158/0008-5472.CAN-09-1947.
   PubMed Web of Science ®Google Scholar
• Parsana P, Riester M, Waldron L. CuratedCRCData: clinically annotated data for the colorectal Cancer transcriptome. Bioconductor. 2013. http://www.bioconductor.org/packages/curatedCRCData/.
   Google Scholar
• Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem. 2000;275:24451–24457.
   PubMed Web of Science ®Google Scholar
• Lee HH, Kim HS, Kang JY, Lee BI, Ha JY, Yoon HJ, Lim SO, Jung G, Suh SW. Crystal structure of human nucleophosmin-core reveals plasticity of the pentamer-pentamer interface. Proteins. 2007;69:672–678. doi:10.1002/prot.21504.
   PubMed Web of Science ®Google Scholar
• Mitrea DM, Grace CR, Buljan M, Yun MK, Pytel NJ, Satumba J, Nourse A, Park C-G, Madan Babu M, White SW, et al. Structural polymorphism in the N-terminal oligomerization domain of NPM1. Proc Natl Acad Sci U S A. 2014;111:4466–4471. doi:10.1073/pnas.1321007111.
   PubMed Web of Science ®Google Scholar
• Yan N, Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol. 2005;21:35–56.
   PubMed Web of Science ®Google Scholar
• Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999;13:152–157. doi:10.1101/gad.13.2.152.
   PubMed Web of Science ®Google Scholar
• Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene. 2002;21:1–8. doi:10.1038/sj.onc.1205020.
   PubMed Web of Science ®Google Scholar
• Agarwal E, Brattain MG, Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal. 2013;25:1711–1719. doi:10.1016/j.cellsig.2013.03.025.
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458:1127–1130.
   PubMed Web of Science ®Google Scholar
• Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 2015;1855:104–121.
   PubMed Web of Science ®Google Scholar
• Papadatos-Pastos D, Rabbie R, Ross P, Sarker D. The role of the PI3K pathway in colorectal cancer. Crit Rev Oncol Hematol. 2015;94:18–30. doi:10.1016/j.critrevonc.2014.12.006.
   PubMed Web of Science ®Google Scholar
• Luo H, Yang Y, Duan J, Wu P, Jiang Q, Xu C. PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis. 2013;4:e481. doi:10.1038/cddis.2013.3.
   PubMed Web of Science ®Google Scholar
• Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008;27:6473–6488.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. doi:10.1126/science.1096502.
   PubMed Web of Science ®Google Scholar
• Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun. 2015;6:7002. doi:10.1038/ncomms8002.
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261–269. doi:10.1016/S0960-9822(06)00122-9.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1101. doi:10.1126/science.1106148.
   PubMed Web of Science ®Google Scholar
• Ahn JY, Liu X, Cheng D, Peng J, Chan PK, Wade PA, Ye K. Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD. Mol Cell. 2005;18:435–445. doi:10.1016/j.molcel.2005.04.010.
   PubMed Web of Science ®Google Scholar
• Lee SB, Xuan Nguyen TL, Choi JW, Lee KH, Cho SW, Liu Z, Ye K, Bae SS, Ahn J-Y. Nuclear Akt interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival. Proc Natl Acad Sci U S A. 2008;105:16584–16589. doi:10.1073/pnas.0807668105.
   PubMed Web of Science ®Google Scholar
• Kim CK, Nguyen TL, Lee SB, Park SB, Lee KH, Cho SW, Ahn JY. Akt2 and nucleophosmin/B23 function as an oncogenic unit in human lung cancer cells. Exp Cell Res. 2011;317:966–975. doi:10.1016/j.yexcr.2010.12.013.
   PubMed Web of Science ®Google Scholar
• Lo SJ, Fan LC, Tsai YF, Lin KY, Huang HL, Wang TH, Liu H, Chen T-C, Huang S-F, Chang C-J, et al. A novel interaction of nucleophosmin with BCL2-associated X protein regulating death evasion and drug sensitivity in human hepatoma cells. Hepatology. 2013;57:1893–1905. doi:10.1002/hep.26209.
   PubMed Web of Science ®Google Scholar
• Chan HJ, Weng JJ, Yung BYM. Nucleophosmin/B23-binding peptide inhibits tumor growth and up-regulates transcriptional activity of p53. Biochem Biophys Res Commun. 2005;333:396–403. doi:10.1016/j.bbrc.2005.04.176.
   PubMed Web of Science ®Google Scholar
• Jian Y, Gao Z, Sun J, Shen Q, Feng F, Jing Y, Yang C. RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene. 2009;28:4201–4211. doi:10.1038/onc.2009.275.
   PubMed Web of Science ®Google Scholar
• Sarduy M, García I, Coca M, Perera A, Torres L, Valenzuela C, Baladrón I, Solares M, Reyes V, Hernández I, et al. Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer. Br J Cancer. 2015;112:1636–1643. doi:10.1038/bjc.2015.137.
   PubMed Web of Science ®Google Scholar
• Destouches D, Page N, Hamma-Kourbali Y, Machi V, Chaloin O, Frechault S, Birmpas C, Katsoris P, Beyrath J, Albanese P, et al. A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. Cancer Res. 2011;71:3296–3305. doi:10.1158/0008-5472.CAN-10-3459.
   PubMed Web of Science ®Google Scholar
• De Cola A, Franceschini M, Di Matteo A, Colotti G, Celani R, Clemente E, Ippoliti R, Cimini AM, Dhez AC, Vallée B, et al. N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy. Cancer Lett. 2018;412:272–282. doi:10.1016/j.canlet.2017.10.038.
   PubMed Web of Science ®Google Scholar